A clinical trial published in The BMJ reveals that dapagliflozin, a drug commonly used to treat type 2 diabetes, may also benefit patients with metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease. The study, conducted in China, found that dapagliflozin improved liver inflammation and reduced fibrosis compared to a placebo, offering new hope for patients with this condition.
The trial involved 154 adults diagnosed with MASH, a condition characterized by excess liver fat and inflammation, which can lead to severe scarring (fibrosis) and cirrhosis. Participants were randomly assigned to receive either 10 mg of dapagliflozin or a placebo daily for 48 weeks. The results showed that 53% of those taking dapagliflozin experienced improved MASH symptoms without worsening fibrosis, compared to only 30% in the placebo group. Additionally, 23% of the dapagliflozin group achieved complete resolution of MASH, versus 8% in the placebo group.
Dapagliflozin also demonstrated significant benefits in reducing liver fibrosis, with 45% of participants showing improvement compared to 20% in the placebo group. The drug was well-tolerated, with very few discontinuing treatments due to adverse effects.
While the study’s findings are promising, the researchers noted limitations, including its focus on a predominantly male, Chinese population, which may affect broader applicability. They emphasized the need for larger, long-term trials to confirm these results.
The study authors concluded, “Our findings indicate that dapagliflozin may affect key aspects of MASH by improving both steatohepatitis and fibrosis.” In a linked editorial, researchers from Argentina highlighted the growing potential for tailored treatments for MASH, stressing the importance of cardiovascular benefits and accessibility for diverse patient populations.
This study marks a significant step forward in the search for effective treatments for MASH, a condition affecting millions worldwide. As research continues, dapagliflozin could become a valuable tool in managing liver disease, particularly for patients with coexisting diabetes. Future trials will further explore its potential and broader implications.
Add comment